Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

World Orphan Drug Congress USA 2025

World Orphan Drug Congress USA 2025
Web Address: WODC USA Website

The World Orphan Drug Congress USA 2025 is the premier gathering for industry experts dedicated to advancing orphan drug development and lifesaving therapies for those living with a rare disease.

With 2,000+ attendees, this event convenes top pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors, and solution providers to drive innovation in the rare disease space.

Why attend?

  • Explore the latest scientific breakthroughs, regulatory updates, and commercial strategies
  • Unparalleled networking and partnership opportunities
  • Gain insights from expert-led keynote discussions and general sessions covering the A-Z of orphan drugs and rare disease

Exclusive 50% discount code – WODC50

Register here

FREE passes for patient advocates and HCPs available here 

🗓️ April 22-24, 2025

📍Boston Convention & Exhibition Center | Boston, MA

Follow #WODC on social media to stay up to date

LinkedIn: https://www.linkedin.com/company/world-orphan-drug-congress-usa/
X: @OrphanConf https://x.com/orphanconf

Further Resources

Close Popup